CohBar, Inc. (CWBR)
Company Description
CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases.
The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes, acute respiratory distress syndrome, cancer, and cardiovascular diseases, such as Alzheimer's disease.
Its lead clinical candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of NASH and obesity.
The company's preclinical programs include CB5138 analogs for fibrotic diseases; and CB5064 analogs for COVID-19 associated ARDS.
CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California.
| Country | United States |
| Founded | 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Dr. Joseph J. Sarret J.D., M.D. |
Contact Details
Address:
1455 Adams Drive, Suite 2050, Menlo Business Park Menlo Park, California 94025 United States | |
| Phone | (650) 446-7888 |
| Website | cohbar.com |
Stock Details
| Ticker Symbol | CWBR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001522602 |
| CUSIP Number | 19249J109 |
| ISIN Number | US19249J1097 |
| Employer ID | 26-1299952 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Joseph J. Sarret J.D., M.D. | Chief Executive Officer and Director |
| Dr. Pinchas Cohen Dean, M.D. | Founder and Member of Scientific Advisory Board |
| Dr. Nir Yacov Barzilai M.D. | Founder and Member of Scientific Advisory Board |
| Prof. John M. Amatruda M.D., Ph.D. | Co-Founder and Member of Scientific Advisory Board |
| Jeffrey F. Biunno CPA, CPA, M.B.A., MBA | Chief Financial Officer, Treasurer and Secretary |
| Jordyn Tarazi | Director of Investor Relations |
| Dr. Kent Grindstaff Ph.D. | Senior Vice President of Research |
| Dr. Nick Vlahakis MBBS | Acting Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 23, 2023 | 425 | Filing |
| May 23, 2023 | 8-K | Current Report |
| May 15, 2023 | 10-Q | Quarterly Report |
| Apr 28, 2023 | 10-K/A | [Amend] Annual report |
| Mar 9, 2023 | 10-K | Annual Report |
| Feb 8, 2023 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 8, 2023 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Dec 7, 2022 | 8-K | Current Report |
| Nov 17, 2022 | 8-K | Current Report |
| Nov 8, 2022 | 10-Q | Quarterly Report |